In order to determine the molecular basis of uroporphyrinogen (URO) decarboxylase deficiency responsible for hepatoerythropoietic porphyria (HEP) and familial porphyria cutanea tarda, we used a human URO decarboxylase cDNA to analyze the organization and expression of the URO decarboxylase gene in lymphoblastoid cells from normal individuals and from two patients with HEP. We could detect neither deletions nor rearrangements in the URO decarboxylase gene. Synthesis, processing, and cell-free translation of the specific transcripts appeared to be normal. The half-life of the abnormal protein was 12 times shorter than that of the normal enzyme. The results indicate that the enzyme defect is due to a rapid degradation of the protein in vivo. This study is the first to provide information regarding the molecular mechanism responsible for the URO decarboxylase deficiency in HEP.
Introduction
Uroporphyrinogen (URO)' decarboxylase (E.C. 4.1.1.31) is a cytosolic enzyme which catalyzes the sequential removal of the four carboxyl groups of the carboxymethyl side chains in uroporphyrinogen to yield coproporphyrinogen (1) . The enzyme has been purified from different sources (2) (3) (4) (5) and antibodies have been obtained against the enzyme. URO decarboxylase deficiency results in the clinical disorders of porphyria cutanea tarda (PCT) and hepatoerythropoietic porphyria (HEP). PCT is characterized clinically by blister formation, increased skin fragility, hypertrichosis, pigmentary changes, and sclerodermoid plaques (1) . The familial form, or type II, ofPCT is characterized by a dominantly inherited deficiency of the enzyme activity (6) (7) (8) ; this deficiency has been documented in all cell types investigated (1) . HEP (9) is a severe form of cutaneous porphyria that occurs very early in infancy and is characterized clinically by photosensitivity, bullae, erosions, hypertrichosis, and redcolored urine. The enzymatic deficiency responsible for the disease is much more severe than in familial PCT. It has been postulated that patients with HEP may be homozygous for the 1 . Abbreviations used in this paper: HEP, hepatoerythropoietic porphyria; PCT, porphyria cutanea tarda; URO, uroporphyrinogen. gene that causes familial PCT in the heterozygous state (10) (11) (12) . However, the situation may be more complicated, since, as in many other genetic diseases, the same clinical syndrome can correspond to different molecular lesions in different families. Therefore, further understanding of the relationship between various conditions associated with a URO decarboxylase defect requires a molecular analysis of the mutation leading to the enzymatic deficiency.
In most cases of familial PCT investigated, immunological and catalytic assays have suggested that the mutation does not lead to the accumulation ofa catalytically inactive gene product (1 1, 13). We obtained the same result in our recent study oftwo HEP patients (1 1). These results indicate either that the URO decarboxylase deficiency is due to a defect in the expression of the gene (gene deletion, defective transcription, abnormal processing of the mRNA, unstable or untranslatable mRNA) or that the protein coded for by the mutant gene is unstable in vivo. In familial PCT, as in most ofthe other dominantly transmitted porphyrias, the characterization of the molecular defect is complicated by the presence of a normal gene coexisting with the mutant allele. In this report we studied a family where the homozygous patients are products of consanguineous parents. The availability of a human URO decarboxylase cDNA clone allowed us to investigate the mutant gene and its expression in lymphoblastoid cell lines.
Methods
Case report. Subjects consisted of two patients (1 and 2) with hepatoerythropoietic porphyria who have been previously described (1 1). URO decarboxylase activity was measured in the 12,000 g supernatant of homogenized lymphoblastoid cells with a previously described method modified for use on a smaller scale (14) . The enzymatic defect was identical to that found in the erythrocytes of the patients (1 1 (16) . RNA electrophoresis was performed in 1% agarose, 2.2 M formaldehyde as described ( 17) and electrophoretic transfer to Zeta-probe was carried out according to the protocol ofthe manufacturer (Bio-Rad Laboratories, Richmond, CA). Filters were hybridized to a nick-translated 32P-labeled DNA probe made from a human cDNA insert of URO decarboxylase Dubart, D. Beaupain, M. Pryor, J. Kushner, M. Cohen-Solal, and M. Goossens, manuscript submitted for publication).
Antibody preparation. The preparation of anti-human uroporphyrinogen decarboxylase antibodies has been previously described (2).
Cellfree translation. Total cellular RNA was denatured at 650C for 5 min, then rapidly cooled on ice and translated in a micrococcal nucleasetreated rabbit reticulocyte lysate system (18). Immunoprecipitations were carried out according to Omary et al. (19) . Translation products were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis according to Laemmli (20) . The gel was treated with Amplify (Amersham Corp., Arlington Heights, IL), dried, and autoradiographed (5 d Blot hybridization of RNA (Northern and dot blots). The presence of the mRNA encoding URO decarboxylase was also studied by hybridization methods. Analyses of lines (one from the homozygous patient 1 and the other from one parent) shown in Fig. 2 (upper part) produced in each case a single radioactive band that indicated the presence of mRNA for URO decarboxylase. In both cases the mRNA migrated with a retardation factor similar to the control cells; it was 1,400 bases in length, in accordance with the previously determined size of the human URO decarboxylase mRNA (21). We performed dot-hybridization between cellular RNA and the specific probe to quantitate the relative amount of specific mRNA compared to the controls (Fig. 2, lower part) . The results clearly demonstrate that the concentration of specific mRNA is very similar in the different cell lines tested.
Characterization ofthe translation products of URO decarboxylase mRNAs in normal and mutant cell lines. The presence of the mRNA in URO decarboxylase-deficient cell lines led us to compare in vitro translation products of URO decarboxylase mRNA both by relative amounts and by molecular size of the protein synthesized. The translated products were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis after immunoprecipitation with URO decarboxylase antiserum (Fig. 3) .
The same amount of neosynthesized URO decarboxylase was found between the normal (Fig. 3, lane 3 ) and the two deficient cell lines (Fig. 3 , lane 5 for patient 1, data not shown for patient 2). The size ofthe protein was determined by comparing the migration of the immunoprecipitated newly synthesized URO decarboxylase to the migrations ofthe purified l4C-labeled (10 ,ug) human enzyme and of other standard proteins on polyacrylamide gels. The molecular weight of the different products was identical to that of the marker enzyme (Fig. 3, lanes 3 and 5, compared to lane 2).
Turnover rate of [3S]methionine-labeled URO decarboxylase. The results reported above suggest that the mRNA encoding the abnormal enzyme is functional. However, the protein is present at a low level (5% of control value) (6). We then performed labeling experiments on lymphoblastoid cell lines to measure the half-life of the enzyme. As shown in Fig. 4 , pulsechase experiments with [35S]methionine-labeled protein demonstrate that the normal enzyme is relatively stable and is degraded with t'/2 of -82 h. In contrast, the abnormal enzyme from the two patients appears to turn over more rapidly: 85% of the labeled protein is lost within 20 h (t'/2, 7 h).
Discussion
The results reported in this paper provide the first details as to the molecular mechanism responsible for the URO decarboxylase deficiency in HEP. Figure 3 . Autoradiograph of a sodium dodecyl sulfate-polyacrylamide gel electrophoresis of proteins translated in vitro and specifically immunoprecipitated by a human URO decarboxylase antibody. Cell-free synthesis was performed in a total reaction mixture of 100 id, containing 25 ug of total RNA from the cell lines. Radioactivity incorporated into trichloroacetic precipitable material was about 2.5 X 106 cpm. Labeled translation products (800,000 cpm) were immunoprecipitated with 1 Ml of antiserum and applied to the electrophoresis gel. Lane (16, (22) (23) (24) . Most of the inherited diseases studied at the molecular level are X-linked or autosomal recessive (25) . For an autosomal dominant disease, the characterization of the molecular defect is complicated by the presence of a normal copy of the gene. Since there is a possibility that HEP represents a homozygous form offamilial PCT (10) (11) (12) , the characterization ofthe mutant gene responsible for HEP in homozygous patients may be an approach to the study of familial PCT. The use of oligonucleotide probes complementary to the normal and the mutant sequences (26) (27) should allow us to determine if the mutations responsible for familial PCT and HEP are identical, or if a heterogeneity exists, as in most of the genetic disorders already investigated at the molecular level.
